ALK5-IN-34 是一种具有口服活性的选择性激活素受体样激酶 (ALK) 抑制剂,可通过 IC50 ≤10 nM 抑制激活素受体样激酶活性,并具有抑制肿瘤生长的作用,可用于癌症等增殖性疾病的研究。
产品编号: MS-O31567 纯度: 98.21% CAS No.: 2785430-90-0 分子式: C23H23N7O 分子量: 413.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

ALK5-IN-34 是一种具有口服活性的选择性激活素受体样激酶 (ALK) 抑制剂,可通过 IC50 ≤10 nM 抑制激活素受体样激酶活性,并具有抑制肿瘤生长的作用,可用于癌症等增殖性疾病的研究。

生物实验数据

生物活性 ALK5-IN-34 is an orally active selective activin receptor-like kinase (ALK) inhibitor that inhibits activin receptor-like kinase activity with an IC50 ≤10 nM and also exhibits tumor growth inhibition, making it useful for research on cancer and other proliferative diseases.
IC50 & Target ALK5:<10 nM
体外研究
(In Vitro)

ALK5-IN-34 (EX-11) has kinase inhibition of ALK5 with an IC50 value of ≤10 nM.
ALK5-IN-34 has kinase selectivity of ALK2/ALK5 with an IC50 value of <100 nM.
ALK5-IN-34 shows TGFB-RI inhibition (RD-SMAD receptor activity) with an IC50 value of ≤100 nM.
ALK5-IN-34 (1 μM-10 nM) inhibits the expression of TGF-β-mediated alpha-SMA in a full concentration-dependent.
ALK5-IN-34 (30, 300 and 3000 nM) suppresses the Treg frequency in a dose dependent manner.
ALK5-IN-34 (0-0.1 μM; for 6 days or 7 days) inhibits FOXL2CI34W-driven growth in KGN and COV434 cells with IC50 values of 140 nM and >10 μM, respectively.
ALK5-IN-34 (10, 100 and 1000 nM; 2 h) shows a dose-dependent decrease in pSmad2 in KGN cell line.
ALK5-IN-34 (30, 300 nM; 24 h) reverses the upregulation of gene expression in dose dependentent.
ALK5-IN-34 (30, 300 nM; 24 h) increases HLA class I expression in dose-dependent.

Cell Viability Assay

Cell Line: KGN and COV434 cell lines
Concentration: 0-0.1 μM
Incubation Time: for 6 days or 7 days
Result: Inhibited FOXL2 CI34W -driven growth.

RT-PCR

Cell Line: Human primary dermal fibroblasts
Concentration: 30, 300 nM
Incubation Time: 24 h
Result: Reversed the upregulation of gene expression with TGFB stimulation.
体内研究
(In Vivo)

ALK5-IN-34 (EX-11) (oral; 10-100 mg/kg) reduces the phopho SMAD2 levels (p-SMAD2) in a dose dependent manner in A549 murine xenograft model.
ALK5-IN-34 (oral; 75 mg/kg; 0-24 h) shows reversely correlated between PK and tumor PD (pSMAD2 levels).
ALK5-IN-34 (oral; 150 mg/kg; bid; for 22 days) increases overall survival in ES-2 ovarian cancer mouse xenograft model and can delay progression.
ALK5-IN-34 (p.o.; 75, 150 mg/kg; twice a day; for 21days) shows tumor growth inhibition (TGI) and increases the survival when combining with anti-PD-L1/anti-PD-1 in Syngeneic TNBC Model and in Subcutaneous Cloudman S91 melanoma model.
ALK5-IN-34 (oral; 300, 1000 mg/kg; bid for 5 days) has good tolerability and safety margin in Tolerability Model.

Animal Model: A549 murine xenograft model
Dosage: 10, 50, 75 and 100 mg/kg
Administration: oral gavage
Result: Exhibited 92.5% inhibition based upon the average p-SMAD2 levels (75 mg/kg).
Animal Model: EMT6 Syngeneic TNBC Model
Dosage: 75, 150 mg/kg
Administration: p.o., twice a day, for 21days
Result: Resulted significantly tumor growth inhibition (TGI) by 37% at 150 mg/kg.
Result in significant tumor growth inhibition (TGI) with combination of anti-PD-LI and resulted in a significant increase in mean survival by 37%.
Resulted in significant TGI by 34% with combination of anti-PD-1 and resulted in significant increase in mean survival by 26%.
Decreased the intra-tumoral pressure.
Animal Model: Cachexia Model
Dosage: 150 mg/kg
Administration: oral gavage, twice a day for 22 days
Result: Showed reduction in total fluid volume and high whole limb weights.
性状 固体
颜色 Light yellow to green yellow

化学信息

分子量 413.48
分子式 C23H23N7O
CAS No. 2785430-90-0

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (241.85 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.4185 mL12.0925 mL24.1850 mL60.4624 mL
5 mM0.4837 mL2.4185 mL4.8370 mL12.0925 mL
10 mM0.2418 mL1.2092 mL2.4185 mL6.0462 mL
15 mM0.1612 mL0.8062 mL1.6123 mL4.0308 mL
20 mM0.1209 mL0.6046 mL1.2092 mL3.0231 mL
25 mM0.0967 mL0.4837 mL0.9674 mL2.4185 mL
30 mM0.0806 mL0.4031 mL0.8062 mL2.0154 mL
40 mM0.0605 mL0.3023 mL0.6046 mL1.5116 mL
50 mM0.0484 mL0.2418 mL0.4837 mL1.2092 mL
60 mM0.0403 mL0.2015 mL0.4031 mL1.0077 mL
80 mM0.0302 mL0.1512 mL0.3023 mL0.7558 mL
100 mM0.0242 mL0.1209 mL0.2418 mL0.6046 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础